RRMS
MCID: RLP002
MIFTS: 55

Relapsing-Remitting Multiple Sclerosis (RRMS) malady

Categories: Neuronal diseases

Aliases & Classifications for Relapsing-Remitting Multiple Sclerosis

Aliases & Descriptions for Relapsing-Remitting Multiple Sclerosis:

Name: Relapsing-Remitting Multiple Sclerosis 12 29 14
Multiple Sclerosis, Relapsing-Remitting 42 69
Multiple Sclerosis Relapsing-Remitting 52
Relapsing-Remitting Ms 12
Rrms 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2378
MeSH 42 D020529
SNOMED-CT 64 426373005
UMLS 69 C0751967

Summaries for Relapsing-Remitting Multiple Sclerosis

Disease Ontology : 12 A multiple sclerosis that is characterized by relapse (attacks of symptom flare-ups) followed by remission (periods of recovery). Symptoms may vary from mild to severe, and relapses and remissions may last for days or months. More than 80 percent of people who have MS begin with relapsing-remitting cycles.

MalaCards based summary : Relapsing-Remitting Multiple Sclerosis, also known as multiple sclerosis, relapsing-remitting, is related to pyridoxal 5'-phosphate-dependent epilepsy and myoglobinuria recurrent. An important gene associated with Relapsing-Remitting Multiple Sclerosis is IFNB1 (Interferon Beta 1), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Glatiramer Acetate and Natalizumab have been mentioned in the context of this disorder. Affiliated tissues include t cells, brain and b cells, and related phenotypes are hematopoietic system and growth/size/body region

Related Diseases for Relapsing-Remitting Multiple Sclerosis

Diseases related to Relapsing-Remitting Multiple Sclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 298)
id Related Disease Score Top Affiliating Genes
1 pyridoxal 5'-phosphate-dependent epilepsy 10.4 IL10 TNF
2 myoglobinuria recurrent 10.3 IFNG IL4
3 severe combined immunodeficiency, t cell-negative, b-cell/natural killer-cell positive 10.3 IFNG IL10 TNF
4 tubular renal disease-cardiomyopathy syndrome 10.3 IL10 IL4 TNF
5 plantar wart 10.3 IFNG IL10 TNF
6 lagophthalmos 10.3 IL10 IL4 TNF
7 conidiobolomycosis 10.3 IL10 IL4 TNF
8 aniseikonia 10.3 IFNG IL17A TNF
9 autosomal dominant deafness-onychodystrophy syndrome 10.3 IFNG IL4 TNF
10 senile reticular retinal degeneration 10.3 IFNG IL10 TNF
11 asymptomatic neurosyphilis 10.3 IFNG IL10 IL4
12 vestibule of mouth cancer 10.3 IL10 IL4 TNF
13 tungiasis 10.3 IFNG IL10 IL4
14 congenital hypothyroidism 10.3 IL10 IL4 TNF
15 centronuclear myopathy 5 10.3 IFNG IL10 IL4
16 rickettsialpox 10.3 IFNG IL10 TNF
17 cryptococcosis 10.3 IL10 IL17A TNF
18 indian plum allergy 10.3 FOXP3 IL10 IL4
19 transient tic disorder 10.3 IL10 IL6 TNF
20 sexual masochism 10.3 CCL5 IFNB1 TNF
21 venezuelan hemorrhagic fever 10.3 ICAM1 IFNG TNF
22 esophagus lymphoma 10.3 IFNG IL6 TNF
23 hypoparathyroidism-retardation-dysmorphism syndrome 10.3 IL10 IL6 TNF
24 ovarian papillary cystadenoma 10.3 FOXP3 IFNG IL4
25 congenital heart defects, hamartomas of tongue, and polysyndactyly 10.3 ICAM1 IL10 IL4
26 phlyctenulosis 10.3 IL10 IL6 TNF
27 cervical adenoid basal carcinoma 10.3 IL10 MBP MOG
28 autoimmune retinopathy 10.3 FOXP3 ICAM1 IL17A
29 lepromatous leprosy 10.3 IFNG IL10 IL6
30 rheumatoid factor-negative juvenile idiopathic arthritis without anti-nuclear antibodies 10.3 IL10 IL6 TNF
31 von economo's disease 10.3 IFNB1 IFNG IL17A MBP
32 reproductive system disease 10.3 IL10 IL17A IL6
33 vps11-related autosomal recessive hypomyelinating leukodystrophy 10.3 CCL5 IL6 TNF
34 primary ciliary dyskinesia 10.3 IL10 IL6 TNF
35 multiple mitochondrial dysfunctions syndrome 10.3 IFNG IL10 IL6
36 heart conduction disease 10.3 IFNG IL10 TNF
37 intracranial arteriosclerosis 10.3 IL6 MBP TNF
38 strawberry gallbladder 10.3 ICAM1 IFNG TNF
39 parkinson disease 11 10.3 IFNG IL10 IL17A TNF
40 cutaneous fibrous histiocytoma 10.3 CCL5 IFNG IL4
41 peripheral artery disease 10.3 IL10 IL4 TNF
42 mikulicz disease 10.3 IL4 IL6 TNF
43 inappropriate adh syndrome 10.2 IL10 IL6 TNF
44 tularemia 10.2 IFNG IL10 IL4 TNF
45 lipomatosis, multiple symmetric 10.2 MBP MOG MX1
46 abnormal retinal correspondence 10.2 IFNG IL10 IL4 TNF
47 choanal atresia, bilateral 10.2 IL17A IL6 TNF
48 crohn's colitis 10.2 IL17A IL6 TNF
49 central nervous system lymphoma 10.2 IL10 IL6 TNF
50 cerebritis 10.2

Graphical network of the top 20 diseases related to Relapsing-Remitting Multiple Sclerosis:



Diseases related to Relapsing-Remitting Multiple Sclerosis

Symptoms & Phenotypes for Relapsing-Remitting Multiple Sclerosis

MGI Mouse Phenotypes related to Relapsing-Remitting Multiple Sclerosis:

44 (show all 21)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.44 MMP9 MOG TIMP1 TNF AQP4 CCL5
2 growth/size/body region MP:0005378 10.42 TNF AQP4 BDNF FOXP3 ICAM1 IFNG
3 immune system MP:0005387 10.41 AQP4 CCL5 FOXP3 ICAM1 IFNB1 IFNG
4 homeostasis/metabolism MP:0005376 10.4 AQP4 BDNF FOXP3 ICAM1 IFNB1 IFNG
5 cellular MP:0005384 10.36 BDNF FOXP3 ICAM1 IFNG IL10 IL18
6 digestive/alimentary MP:0005381 10.35 TNF IL6 MMP9 AQP4 BDNF FOXP3
7 behavior/neurological MP:0005386 10.34 AQP4 BDNF FOXP3 IFNG IL10 IL18
8 mortality/aging MP:0010768 10.32 IL4 AQP4 BDNF FOXP3 ICAM1 IFNG
9 endocrine/exocrine gland MP:0005379 10.3 AQP4 BDNF FOXP3 ICAM1 IFNG IL10
10 cardiovascular system MP:0005385 10.29 ICAM1 IFNG IL10 IL18 IL6 MMP9
11 nervous system MP:0003631 10.22 BDNF ICAM1 AQP4 IFNB1 IFNG IL10
12 integument MP:0010771 10.19 MMP9 TNF BDNF FOXP3 ICAM1 IFNG
13 craniofacial MP:0005382 10.12 BDNF FOXP3 IFNG IL10 IL17A IL4
14 muscle MP:0005369 10.06 ICAM1 IFNG IL10 IL18 IL6 MMP9
15 neoplasm MP:0002006 10.03 ICAM1 IFNB1 IFNG IL10 IL6 MMP9
16 no phenotypic analysis MP:0003012 10.02 AQP4 BDNF FOXP3 IFNB1 IFNG IL10
17 reproductive system MP:0005389 9.96 BDNF FOXP3 IFNG IL10 IL4 IL6
18 respiratory system MP:0005388 9.9 AQP4 BDNF FOXP3 IFNG IL10 IL17A
19 renal/urinary system MP:0005367 9.87 AQP4 FOXP3 IFNG IL17A IL4 IL6
20 skeleton MP:0005390 9.61 IL10 IFNB1 IFNG IL17A IL4 IL6
21 vision/eye MP:0005391 9.44 AQP4 BDNF FOXP3 ICAM1 IFNG IL10

Drugs & Therapeutics for Relapsing-Remitting Multiple Sclerosis

Drugs for Relapsing-Remitting Multiple Sclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 333)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Glatiramer Acetate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147245-92-9 3081884
2
Natalizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 189261-10-7
3
Interferon beta-1b Approved Phase 4,Phase 3,Phase 2,Phase 1 145155-23-3
4
Interferon beta-1a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 145258-61-3 6438354
5
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
6
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
7
Simvastatin Approved Phase 4,Phase 3 79902-63-9 54454
8
alemtuzumab Approved, Investigational Phase 4,Phase 3,Phase 2 216503-57-0
9
Dimethyl fumarate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 624-49-7 637568 5271565
10
Aspirin Approved, Vet_approved Phase 4,Early Phase 1 50-78-2 2244
11
Mitoxantrone Approved, Investigational Phase 4,Phase 2,Phase 3 65271-80-9 4212
12
Acetaminophen Approved Phase 4 103-90-2 1983
13
Cetirizine Approved Phase 4 83881-51-0 2678
14
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
15
Histamine Approved, Investigational Phase 4,Phase 2 75614-87-8, 51-45-6 774
16
Ibuprofen Approved Phase 4 15687-27-1 3672
17
Ranitidine Approved Phase 4 66357-59-3, 66357-35-5 3001055
18
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 1,Early Phase 1 50-02-2 5743
19
Methotrexate Approved Phase 4,Early Phase 1 1959-05-2, 59-05-2 126941
20
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
21
Iron Approved Phase 4 7439-89-6 23925
22
Donepezil Approved Phase 4 120014-06-4 3152
23
Glycerol Approved, Experimental Phase 4 56-81-5 753
24 Titanium dioxide Approved Phase 4 13463-67-7
25
Prednisone Approved, Vet_approved Phase 4,Phase 2 53-03-2 5865
26
Fluoxetine Approved, Vet_approved Phase 4,Phase 2 54910-89-3 3386
27
Citalopram Approved Phase 4 59729-33-8 2771
28
Norepinephrine Approved Phase 4 51-41-2 439260
29
Loperamide Approved Phase 4 53179-11-6 3955
30 Simethicone Approved Phase 4
31
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
32
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 5538
33
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 67-97-0 6221 10883523 5280795
34
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 50-14-6 5280793
35
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Early Phase 1 59-30-3 6037
36
leucovorin Approved, Nutraceutical Phase 4,Early Phase 1 58-05-9 54575, 6560146 143
37
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
38
Menadione Approved, Nutraceutical Phase 4,Phase 3 58-27-5 4055
39
Phytonadione Approved, Nutraceutical Phase 4,Phase 3 84-80-0 4812 5284607
40 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
41 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 Fingolimod Hydrochloride Phase 4,Phase 3,Phase 2,Phase 1
44 Antioxidants Phase 4,Phase 2,Phase 3,Phase 1
45 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1
46 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
47 Retinol palmitate Phase 4
48 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1
49 Vitamins Phase 4,Phase 3,Phase 2,Phase 1
50 Krestin Phase 4,Phase 1,Phase 2

Interventional clinical trials:

(show top 50) (show all 490)
id Name Status NCT ID Phase
1 Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS) Unknown status NCT00910598 Phase 4
2 Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya Unknown status NCT02325440 Phase 4
3 Impact of Vitamin A on Multiple Sclerosis (MS) Unknown status NCT01417273 Phase 4
4 Impact of Vitamin A on Gene Expression, in Multiple Sclerosis Patient Unknown status NCT01407211 Phase 4
5 Impact of Vitamin A on RAR Gene Expression in Multiple Sclerosis Unknown status NCT01705457 Phase 4
6 Colecalciferol as an Add-on Treatment to Interferon-beta-1b for Treatment of Multiple Sclerosis (MS) Unknown status NCT01339676 Phase 4
7 Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI Unknown status NCT00176592 Phase 4
8 Rebif® Rebidose® Versus Rebiject II® Ease-of-Use Completed NCT02019550 Phase 4
9 Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis Completed NCT01310166 Phase 4
10 Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany Completed NCT02125604 Phase 4
11 Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis Completed NCT02090413 Phase 4
12 A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Completed NCT00871780 Phase 4
13 Fingolimod -Response According to Coping - Evaluation Completed NCT01420055 Phase 4
14 Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis Completed NCT00078338 Phase 4
15 Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif Completed NCT00317941 Phase 4
16 Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. Completed NCT01623596 Phase 4
17 Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC) Completed NCT01534182 Phase 4
18 Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy Completed NCT01498887 Phase 4
19 Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Completed NCT02142205 Phase 4
20 A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device Completed NCT01791244 Phase 4
21 Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients Completed NCT01201343 Phase 4
22 An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS Completed NCT00206648 Phase 4
23 Natalizumab De-escalation With Interferon Beta-1b Completed NCT01144052 Phase 4
24 A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis Completed NCT02064816 Phase 4
25 Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01) Completed NCT02720107 Phase 4
26 Fingolimod Effect on Cytokine and Chemokine Levels Completed NCT02373098 Phase 4
27 A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone Completed NCT01142466 Phase 4
28 Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS Completed NCT00168766 Phase 4
29 fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls Completed NCT00391352 Phase 4
30 Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change Completed NCT01317004 Phase 4
31 Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis Completed NCT00367484 Phase 4
32 Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta Completed NCT00493116 Phase 4
33 Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies Completed NCT00492466 Phase 4
34 Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis Completed NCT00492765 Phase 4
35 Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA Completed NCT02205489 Phase 4
36 Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MS Completed NCT00232193 Phase 4
37 Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a? Completed NCT00534261 Phase 4
38 NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness Completed NCT01591551 Phase 4
39 AVONEX® Combination Trial - "ACT" Completed NCT00112034 Phase 4
40 Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis Completed NCT00246324 Phase 4
41 Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial Completed NCT01085318 Phase 4
42 FOCUS Fatigue Outcome in Copaxone USers Completed NCT00267319 Phase 4
43 Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients Completed NCT01225289 Phase 4
44 A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties Completed NCT00315367 Phase 4
45 A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis Completed NCT00203086 Phase 4
46 Efficacy of Fish Oil in Multiple Sclerosis Completed NCT01842191 Phase 4
47 Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities Completed NCT01456416 Phase 4
48 Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms Completed NCT01333501 Phase 4
49 STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START) Completed NCT01585298 Phase 4
50 A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720 Completed NCT01578330 Phase 4

Search NIH Clinical Center for Relapsing-Remitting Multiple Sclerosis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: multiple sclerosis, relapsing-remitting

Genetic Tests for Relapsing-Remitting Multiple Sclerosis

Genetic tests related to Relapsing-Remitting Multiple Sclerosis:

id Genetic test Affiliating Genes
1 Relapsing Remitting Multiple Sclerosis 29

Anatomical Context for Relapsing-Remitting Multiple Sclerosis

MalaCards organs/tissues related to Relapsing-Remitting Multiple Sclerosis:

39
T Cells, Brain, B Cells, Testes, Bone, Thyroid, Spinal Cord

Publications for Relapsing-Remitting Multiple Sclerosis

Articles related to Relapsing-Remitting Multiple Sclerosis:

(show top 50) (show all 706)
id Title Authors Year
1
Acute pneumonitis and pericarditis related to alemtuzumab therapy in relapsing-remitting multiple sclerosis. ( 27888417 )
2017
2
A discrete event simulation to model the cost-utility of fingolimod and natalizumab in rapidly evolving severe relapsing-remitting multiple sclerosis in the UK. ( 28008769 )
2017
3
Comparative effectiveness of interferons in relapsing-remitting multiple sclerosis: a meta-analysis of real-world studies. ( 28027680 )
2017
4
An interleukin 12 B single nucleotide polymorphism increases IL-12p40 production and is associated with increased disease susceptibility in patients with relapsing-remitting multiple sclerosis. ( 28276258 )
2017
5
Down-regulation of CYP27B1 gene expression in Iranian patients with relapsing-remitting multiple sclerosis. ( 27792005 )
2016
6
Fingolimod for relapsing-remitting multiple sclerosis. ( 27091121 )
2016
7
Association of seasonal serum 25-hydroxyvitamin D levels with disability and relapses in relapsing-remitting multiple sclerosis. ( 27026420 )
2016
8
Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis. ( 27552111 )
2016
9
Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis. ( 27645339 )
2016
10
Activated IL-1RI Signaling Pathway Induces Th17 Cell Differentiation via Interferon Regulatory Factor 4 Signaling in Patients with Relapsing-Remitting Multiple Sclerosis. ( 27965670 )
2016
11
Fluctuations of spontaneous EEG topographies predict disease state in relapsing-remitting multiple sclerosis. ( 27625987 )
2016
12
Myelin Basic Protein-Induced Production of Tumor Necrosis Factor-I+ and Interleukin-6, and Presentation of the Immunodominant Peptide MBP85-99 by B Cells from Patients with Relapsing-Remitting Multiple Sclerosis. ( 26756931 )
2016
13
Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies. ( 27645341 )
2016
14
Andrographis paniculata decreases fatigue in patients with relapsing-remitting multiple sclerosis: a 12-month double-blind placebo-controlled pilot study. ( 27215274 )
2016
15
The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada. ( 27080475 )
2016
16
Regulatory Cell Populations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients: Effect of Disease Activity and Treatment Regimens. ( 27571060 )
2016
17
Assessment of Serum Nitrogen Species and Inflammatory Parameters in Relapsing-Remitting Multiple Sclerosis Patients Treated with Different Therapeutic Approaches. ( 28078290 )
2016
18
High dose Vitamin D intake and quality of life in relapsing-remitting multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. ( 27597724 )
2016
19
Altered molecular expression of TLR-signaling pathways affects the steady-state release of IL-12p70 and IFN-I+ in patients with relapsing-remitting multiple sclerosis. ( 27036414 )
2016
20
Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. ( 27880972 )
2016
21
Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy. ( 27027097 )
2016
22
Regional Frontal Perfusion Deficits in Relapsing-Remitting Multiple Sclerosis with Cognitive Decline. ( 27197989 )
2016
23
Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree. ( 27639853 )
2016
24
Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNI^; the SOLARIUM study. ( 27806875 )
2016
25
Hypoperfusion of the thalamus is associated with disability in relapsing remitting multiple sclerosis. ( 27865557 )
2016
26
An update on the evidence base for peginterferon I^1a in the treatment of relapsing-remitting multiple sclerosis. ( 27800024 )
2016
27
Combination treatment of fingolimod with antidepressants in relapsing-remitting multiple sclerosis patients with depression: a multicentre, open-label study - REGAIN. ( 27582893 )
2016
28
Baseline Differences in Minor Lymphocyte Subpopulations may Predict Response to Fingolimod in Relapsing-Remitting Multiple Sclerosis Patients. ( 27080413 )
2016
29
Laquinimod in the treatment of relapsing remitting multiple sclerosis. ( 27089834 )
2016
30
Predictors of first-line treatment persistence in a Portuguese cohort of relapsing-remitting multiple sclerosis. ( 27542939 )
2016
31
Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. ( 27885061 )
2016
32
Autoantigen-specific immunosuppression with tolerogenic peripheral blood cells prevents relapses in a mouse model of relapsing-remitting multiple sclerosis. ( 27131971 )
2016
33
Monitoring interferon I^ treatment response with magnetic resonance spectroscopy in relapsing remitting multiple sclerosis. ( 27603381 )
2016
34
Single nucleotide polymorphisms in the FOXP3 gene are associated with increased risk of relapsing-remitting multiple sclerosis. ( 27792007 )
2016
35
Altered intra- and interregional synchronization in relapsing-remitting multiple sclerosis: a resting-state fMRI study. ( 27143886 )
2016
36
Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis. ( 27730845 )
2016
37
HLA genes as modifiers of response to IFN-I^-1a therapy in relapsing-remitting multiple sclerosis. ( 27020477 )
2016
38
Multimodal quantitative MRI assessment of cortical damage in relapsing-remitting multiple sclerosis. ( 27153293 )
2016
39
Neurovascular coupling in patients with relapsing-remitting multiple sclerosis. ( 27136094 )
2016
40
Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study. ( 27888416 )
2016
41
The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis. ( 27822961 )
2016
42
Fulminant Central Nervous System Nocardiosis in a Patient Treated With Alemtuzumab For Relapsing-Remitting Multiple Sclerosis. ( 27043129 )
2016
43
No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study. ( 28080250 )
2016
44
Long-Term Adherence to IFN Beta-1a Treatment when Using RebiSmartAr Device in Patients with Relapsing-Remitting Multiple Sclerosis. ( 27526201 )
2016
45
Functional and structural cerebral changes in key brain regions after a facilitation programme for episodic future thought in relapsing-remitting multiple sclerosis patients. ( 27045451 )
2016
46
Functional cortical changes in relapsing-remitting multiple sclerosis at amplitude configuration: a resting-state fMRI study. ( 27932883 )
2016
47
Quantitative Evaluation of BAFF, HMGB1, TLR 4 AND TLR 7 Expression in Patients with Relapsing Remitting Multiple Sclerosis. ( 26996115 )
2016
48
Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis. ( 27533512 )
2016
49
Cardiac Safety Profile of First Dose of Fingolimod for Relapsing-Remitting Multiple Sclerosis in Real-World Settings: Data from a German Prospective Multi-Center Observational Study. ( 27624575 )
2016
50
Commentary: Acute Hemorrhagic Leukoencephalitis (Weston-Hurst Syndrome) in a Patient with Relapse-Remitting Multiple Sclerosis. ( 27252706 )
2016

Variations for Relapsing-Remitting Multiple Sclerosis

Expression for Relapsing-Remitting Multiple Sclerosis

Search GEO for disease gene expression data for Relapsing-Remitting Multiple Sclerosis.

Pathways for Relapsing-Remitting Multiple Sclerosis

Pathways related to Relapsing-Remitting Multiple Sclerosis according to GeneCards Suite gene sharing:

(show top 50) (show all 66)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.12 CCL5 ICAM1 IFNA1 IFNB1 IFNG IL10
2
Show member pathways
13.75 BDNF CCL5 IFNA1 IFNB1 IFNG IL10
3
Show member pathways
13.63 BDNF CCL5 ICAM1 IFNA1 IFNB1 IFNG
4
Show member pathways
13.5 BDNF CCL5 IL10 IL17A IL18 IL4
5
Show member pathways
13.4 BDNF CCL5 IL10 IL17A IL18 IL4
6
Show member pathways
13.28 CCL5 ICAM1 IFNA1 IFNB1 IFNG IL10
7
Show member pathways
13.04 CCL5 IFNA1 IFNB1 IL18 IL6 TNF
8
Show member pathways
13.02 CCL5 IFNA1 IFNB1 IFNG IL10 IL6
9
Show member pathways
12.98 FOXP3 ICAM1 IFNA1 IFNG IL10 IL17A
10
Show member pathways
12.87 CCL5 ICAM1 IFNA1 IFNB1 IFNG IL18
11
Show member pathways
12.85 CCL5 IFNA1 IFNB1 IFNG IL18 IL6
12
Show member pathways
12.74 FOXP3 IFNG IL10 IL17A IL18 IL4
13
Show member pathways
12.71 IFNG IL10 IL17A IL18 IL6 TIMP1
14
Show member pathways
12.69 IFNG IL10 IL18 IL4 TNF
15 12.66 CCL5 FOXP3 IFNA1 IFNG IL10 IL17A
16
Show member pathways
12.63 ICAM1 IFNA1 IFNB1 IFNG IL4 TNF
17
Show member pathways
12.61 ICAM1 IFNA1 IFNB1 IFNG MX1
18
Show member pathways
12.56 IFNG IL10 IL17A IL4 IL6 TNF
19
Show member pathways
12.46 CCL5 ICAM1 IFNG IL4 IL6 TNF
20
Show member pathways
12.46 IFNG IL17A IL4 IL6 MMP9 TNF
21
Show member pathways
12.35 IFNA1 IFNB1 IFNG IL6
22 12.35 IFNA1 IFNB1 IFNG IL10 IL18 IL6
23
Show member pathways
12.34 IFNA1 IFNB1 IFNG IL10 IL4 IL6
24
Show member pathways
12.31 IFNG IL10 IL4 TNF
25
Show member pathways
12.31 IFNB1 IFNG IL4 IL6 TNF
26 12.3 AQP4 BDNF IL10 IL6 TNF
27 12.24 IFNG IL6 MMP9 TNF
28 12.16 ICAM1 IFNG MMP9 TNF
29 12.13 IFNG IL10 IL4 IL6 TNF
30
Show member pathways
12.11 IFNG IL10 IL17A IL18 IL6 TNF
31 12.09 CCL5 ICAM1 IL6 MMP9 TNF
32
Show member pathways
12.02 IFNG IL17A IL4 IL6
33 11.99 IFNG IL10 IL6 TNF
34 11.99 AQP4 BDNF ICAM1 IFNG IL4 IL6
35
Show member pathways
11.97 FOXP3 ICAM1 IL17A IL6
36 11.96 CCL5 ICAM1 IFNG IL17A IL18 IL6
37 11.93 IFNG IL10 IL17A IL18 IL4 TNF
38 11.91 ICAM1 IFNG IL4 IL6
39 11.9 IFNB1 IFNG IL10 IL6 TNF
40
Show member pathways
11.87 FOXP3 IFNG IL4 TNF
41 11.87 ICAM1 IL10 IL17A IL18 IL4 IL6
42 11.86 FOXP3 ICAM1 IL10 IL4 IL6 TNF
43
Show member pathways
11.86 IFNA1 IFNB1 IFNG IL10 IL17A IL18
44 11.84 IFNA1 IFNB1 IFNG IL10 IL6
45
Show member pathways
11.81 ICAM1 IFNG IL6 MMP9 TNF
46 11.79 IL10 IL6 TNF
47 11.79 CCL5 IL4 IL6 MMP9 TIMP1 TNF
48 11.66 ICAM1 IL6 MMP9 TNF
49 11.66 ICAM1 IFNG IL10 IL18 IL6 TNF
50 11.65 IL18 IL6 TNF

GO Terms for Relapsing-Remitting Multiple Sclerosis

Cellular components related to Relapsing-Remitting Multiple Sclerosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 BDNF CCL5 CD52 IFNA1 IFNB1 IFNG
2 external side of plasma membrane GO:0009897 9.7 AQP4 ICAM1 IFNG IL17A IL4 IL6
3 extracellular space GO:0005615 9.44 CCL5 ICAM1 IFNA1 IFNB1 IFNG IL10

Biological processes related to Relapsing-Remitting Multiple Sclerosis according to GeneCards Suite gene sharing:

(show top 50) (show all 69)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of protein phosphorylation GO:0001934 9.99 IFNG IL4 MMP9 TNF
2 defense response GO:0006952 9.98 IFNA1 IFNB1 MX1 TNF
3 defense response to virus GO:0051607 9.96 IFNA1 IFNB1 IFNG IL6 MX1
4 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.93 IL10 IL4 IL6 TNF
5 positive regulation of protein kinase B signaling GO:0051897 9.91 IL18 IL6 TNF
6 cellular response to organic cyclic compound GO:0071407 9.91 CCL5 IL18 TNF
7 response to glucocorticoid GO:0051384 9.9 IL10 IL6 TNF
8 response to insulin GO:0032868 9.9 ICAM1 IL10 IL6
9 regulation of insulin secretion GO:0050796 9.9 CCL5 IFNG TNF
10 type I interferon signaling pathway GO:0060337 9.89 IFNA1 IFNB1 MX1
11 cellular response to interferon-gamma GO:0071346 9.89 AQP4 CCL5 ICAM1
12 cellular response to interleukin-1 GO:0071347 9.89 CCL5 ICAM1 IL17A IL6
13 cellular response to lipopolysaccharide GO:0071222 9.88 ICAM1 IFNG IL10 IL6 TNF
14 positive regulation of cell adhesion GO:0045785 9.87 CCL5 IFNG TNF
15 B cell differentiation GO:0030183 9.87 IFNA1 IFNB1 IL10 IL4
16 positive regulation of T cell proliferation GO:0042102 9.85 CCL5 IFNG IL4 IL6
17 cellular response to dexamethasone stimulus GO:0071549 9.84 ICAM1 IFNB1 IL6
18 response to cytokine GO:0034097 9.84 CCL5 IL4 IL6 TIMP1
19 B cell proliferation GO:0042100 9.83 IFNA1 IFNB1 IL10
20 positive regulation of smooth muscle cell proliferation GO:0048661 9.83 CCL5 IL18 IL6 TNF
21 lipopolysaccharide-mediated signaling pathway GO:0031663 9.81 CCL5 IL18 TNF
22 negative regulation of endothelial cell apoptotic process GO:2000352 9.81 ICAM1 IL10 IL4
23 negative regulation of interleukin-6 production GO:0032715 9.8 FOXP3 IL10 TNF
24 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.79 IFNA1 IFNB1 IFNG
25 positive regulation of osteoclast differentiation GO:0045672 9.78 IFNG IL17A TNF
26 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.76 IL10 MMP9 TNF
27 positive regulation of nitric oxide biosynthetic process GO:0045429 9.76 ICAM1 IFNG IL6 TNF
28 negative regulation of growth of symbiont in host GO:0044130 9.75 IFNG IL10 TNF
29 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.74 IL10 TNF
30 cellular response to nutrient levels GO:0031669 9.74 ICAM1 IL6
31 negative regulation of cytokine secretion GO:0050710 9.74 FOXP3 IL6
32 positive regulation of protein import into nucleus, translocation GO:0033160 9.74 IFNG IL6
33 negative regulation of interleukin-17 production GO:0032700 9.73 FOXP3 IFNG
34 positive regulation of isotype switching to IgG isotypes GO:0048304 9.73 IFNG IL4
35 myeloid cell homeostasis GO:0002262 9.73 FOXP3 IL6
36 negative regulation of lipid storage GO:0010888 9.72 IL6 TNF
37 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.72 IL10 MBP
38 endothelial cell apoptotic process GO:0072577 9.71 IL10 TNF
39 positive regulation of T-helper 2 cell differentiation GO:0045630 9.71 IL18 IL6
40 negative regulation of membrane protein ectodomain proteolysis GO:0051045 9.71 IL10 TIMP1
41 negative regulation of viral genome replication GO:0045071 9.71 CCL5 IFNB1 MX1 TNF
42 negative regulation of cytokine secretion involved in immune response GO:0002740 9.7 IL10 TNF
43 epithelial cell proliferation involved in salivary gland morphogenesis GO:0060664 9.7 IL6 TNF
44 positive regulation of receptor binding GO:1900122 9.7 BDNF MMP9
45 positive regulation of interleukin-23 production GO:0032747 9.69 IFNG IL17A
46 positive regulation of chemokine biosynthetic process GO:0045080 9.69 IFNG IL4 TNF
47 regulation of isotype switching GO:0045191 9.68 IL10 IL4
48 negative regulation of T-helper 17 cell differentiation GO:2000320 9.68 FOXP3 IL4
49 negative regulation of chronic inflammatory response GO:0002677 9.67 FOXP3 IL4
50 positive regulation of mononuclear cell migration GO:0071677 9.67 IL4 TNF

Molecular functions related to Relapsing-Remitting Multiple Sclerosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.36 CCL5 IFNA1 IFNB1 IFNG IL10 IL17A
2 growth factor activity GO:0008083 9.35 BDNF IL10 IL4 IL6 TIMP1
3 cytokine receptor binding GO:0005126 9.33 IFNA1 IFNB1 IL4

Sources for Relapsing-Remitting Multiple Sclerosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....